Stay updated with breaking news from Symptom Control. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 -- Crinetics Pharmaceuticals, Inc. today announced upcoming... | June 9, 2023
Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)
Introduction: Persistent breathlessness is a debilitating symptom that is prevalent in the community, particularly in people with chronic and life-limiting illnesses. Treatment includes different steps, including pharmacological treatment aiming to improve the symptom and optimize people’s wellbeing. Areas covered: PubMed and Google Scholar were screened using ‘chronic breathlessness’ OR ‘persistent breathlessness,’ AND ‘pharmacological treatment,’ OR ‘opioids.’ This review focuses on pharmacological treatments to reduce persistent breathlessness and discusses possible mechan...
/PRNewswire/ -- Health Union, the leader in social health, has been accepted to present research about irritable bowel syndrome symptom control, relationships...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID).